No abstract

No abstract

Summary An investigation of 8,000 ante‐natal patients showed that 260 had a positive “modified” indirect anti‐human globulin test against A1 and/or B human red cells. In 116 cases the patient was ABO incompatible with her husband. A diagnosis of ABO haemolytic disease of the newborn was made on 24 babies born to these 116 patients. Three babies were exchange transfused. Using the information gained from this investigation we propose and describe a scheme suitable for the routine ante‐natal prediction of ABO haemolytic disease of the newborn. Résumé Des examens anténatals pratiqués chez 8000 malades ont démontré que 260 personnes avaient un test indirect à I'anti‐globuline humaine modifié positif contre les érythrocytes humains A1 ou B. Dans 116 cas, 1a malade était incompatible dans le système ABO avec son mari. Un diagnostic de maladie hémolytique du nouveau‐né selon le système ABO a été fait chez 24 enfants issus de ces 116 patientes. Trois enfants ont été exsanguinotransfusés. Grâce aux informations obtenues à la suite de ces recherches, les auteurs proposent et décrivent un schéma utilisable pour la détection anténatale des maladies hémolytiques du nouveau‐né dans le système ABO. Zusammenfassung Innerhalb einer Untersuchungsreihe, die 8000 Schwangerenseren umfaßte, wurde bei 260 Seren ein positiver «modifizierter» indirekter Antiglobulintest gegen Aj und/oder B‐Erythrozyten festgestellt. In 116 Fällen erwies sich die Schwangere gegenüber ihrem Ehemann als ABO‐inkompatibel. Bei 24 Neugeborenen dieser 116 Schwangeren wurde ein ABO‐Morbus haemolyticus festgestellt, der in drei Fällen eine Austauschtransfusion nütig machte. Auf Grand der im Rahmen dieser Untersuchungen gewonnenen Erfahrungen wird ein Schema für das Routinevorgehen hinsichtlich der vorgeburtlichen Erfassung von ABO‐Morbus haemolyticus‐Fällen vorgeschlagen.

No abstract

A series of 287 patients referred by their family doctors with symptoms of bladder outflow obstruction were asked to attend the hospital for "pre-clinic" screening for carcinoma of prostate (CaP). Blood samples were collected from 211 patients and analysed for serum prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). Thirty-six patients had a serum PSA greater than 10 micrograms/l and 7 had PAP levels greater than 5 iu/l. In no instance was the PAP elevated without an associated increase in PSA concentration. Patients with raised markers underwent further investigations which included prostatic biopsy and/or resection; 17 patients were proved to have carcinoma of the prostate, 9 of whom had distant metastases. The specificity of PSA for detecting prostate cancer in this study was 90% with a sensitivity of 89.5%, in contrast to values for PAP of 100% and 36.8%. The routine use of PAP as a marker for prostatic cancer should be abandoned. The use of PSA as a screening test in a group of patients with prostatism appears justified, but with a positive predictive value of only 47%, its use in a mass unselected screening programme is not recommended.